Abstract
Introduction
Photodynamic therapy (PDT) is a two-step treatment involving the administration of a photosensitive agent followed by its activation at a specific light wavelength for targeting of tumor cells.
Materials/Methods
A comprehensive review of the literature was performed to analyze the indications for PDT, mechanisms of action, use of different photosensitizers, the immunomodulatory effects of PDT, and both preclinical and clinical studies for use in high-grade gliomas (HGGs).
Results
PDT has been approved by the United States Food and Drug Administration (FDA) for the treatment of premalignant and malignant diseases, such as actinic keratoses, Barrett’s esophagus, esophageal cancers, and endobronchial non-small cell lung cancers, as well as for the treatment of choroidal neovascularization. In neuro-oncology, clinical trials are currently underway to demonstrate PDT efficacy against a number of malignancies that include HGGs and other brain tumors. Both photosensitizers and photosensitizing precursors have been used for PDT. 5-aminolevulinic acid (5-ALA), an intermediate in the heme synthesis pathway, is a photosensitizing precursor with FDA approval for PDT of actinic keratosis and as an intraoperative imaging agent for fluorescence-guided visualization of malignant tissue during glioma surgery. New trials are underway to utilize 5-ALA as a therapeutic agent for PDT of the intraoperative resection cavity and interstitial PDT for inoperable HGGs.
Conclusion
PDT remains a promising therapeutic approach that requires further study in HGGs. Use of 5-ALA PDT permits selective tumor targeting due to the intracellular metabolism of 5-ALA. The immunomodulatory effects of PDT further strengthen its use for treatment of HGGs and requires a better understanding. The combination of PDT with adjuvant therapies for HGGs will need to be studied in randomized, controlled studies.
Similar content being viewed by others
References
Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-Oncology 18:v1–v75. https://doi.org/10.1093/neuonc/now207
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-O (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC, Carter BS, Chen CC (2016) Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neuro-Oncology Pract 3:29–38. https://doi.org/10.1093/nop/npv016
Smoll NR, Hamilton B (2014) Incidence and relative survival of anaplastic astrocytomas. Neuro-Oncology 16:1400–1407. https://doi.org/10.1093/neuonc/nou053
(2018) Glioblastoma (GBM). https://www.abta.org/tumor_types/glioblastoma-gbm/
Lee Titsworth W, Murad GJ, Hoh BL, Rahman M (2014) Fighting fire with fire: the revival of thermotherapy for gliomas. Anticancer Res 34:565–574
Sun J, Guo M, Pang H, Qi J, Zhang J, Ge Y (2013) Treatment of malignant glioma using hyperthermia. Neural Regen Res 8:2775–2782. https://doi.org/10.3969/j.issn.1673-5374.2013.29.009
Reznik E, Smith AW, Taube S, Mann J, Yondorf MZ, Parashar B, Wernicke AG (2018) Radiation and immunotherapy in high-grade gliomas: where do we stand? Am J Clin Oncol 41:197–212. https://doi.org/10.1097/coc.0000000000000406
Akimoto J (2016) Photodynamic therapy for malignant brain tumors. Neurol Med-Chir 56:151–157. https://doi.org/10.2176/nmc.ra.2015-0296
Stepp H, Stummer W (2018) 5-ALA in the management of malignant glioma. Lasers Surg Med 50:399–419. https://doi.org/10.1002/lsm.22933
DM D, HJ S (1991) A history of photodynamic therapy. Australian and New Zealand. J Surg 61:340–348. https://doi.org/10.1111/j.1445-2197.1991.tb00230.x
Castano AP, Demidova TN, Hamblin MR (2004) Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 1:279–293. https://doi.org/10.1016/S1572-1000(05)00007-4
Castano AP, Demidova TN, Hamblin MR (2005) Mechanisms in photodynamic therapy: part two—cellular signaling, cell metabolism and modes of cell death. Photodiagn Photodyn Ther 2:1–23. https://doi.org/10.1016/S1572-1000(05)00030-X
Kawase Y, Iseki H (2013) Parameter-finding studies of photodynamic therapy for approval in Japan and the USA. Photodiagn Photodyn Ther 10:434–445. https://doi.org/10.1016/j.pdpdt.2013.03.001
(2015) Photodynamic Therapy. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/photodynamic-therapy.html
Kessel D (2018) Apoptosis, paraptosis and autophagy: death and survival pathways associated with photodynamic therapy. Photochem Photobiol. https://doi.org/10.1111/php.12952
Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR (2011) Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) 3:2516–2539. https://doi.org/10.3390/cancers3022516
Hirschberg H, Sun C-H, Tromberg BJ, Yeh AT, Madsen SJ (2004) Enhanced cytotoxic effects of 5-aminolevulinic acid-mediated photodynamic therapy by concurrent hyperthermia in glioma spheroids. J Neuro-Oncol 70:289–299. https://doi.org/10.1007/s11060-004-9161-7
Karmakar S, Banik NL, Patel SJ, Ray SK (2007) 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. Neurosci Lett 415:242–247. https://doi.org/10.1016/j.neulet.2007.01.071
Coupienne I, Fettweis G, Rubio N, Agostinis P, Piette J (2011) 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochemical & photobiological sciences: official journal of the European Photochemistry Association and the European Society for Photobiology. Photochem Photobiol Sci 10: 1868–1878 https://doi.org/10.1039/c1pp05213f
Coupienne I, Bontems S, Dewaele M, Rubio N, Habraken Y, Fulda S, Agostinis P, Piette J (2011) NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem Pharmacol 81:606–616. https://doi.org/10.1016/j.bcp.2010.12.015
Cengel KA, Simone CB, Busch TM Vascular effects of photodynamic therapy for tumors. Handbook of photodynamic therapy. University of Toronto, Canada, pp 335–364
Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6:535–545. https://doi.org/10.1038/nrc1894
Garg AD, Nowis D, Golab J, Agostinis P (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15:1050–1071. https://doi.org/10.1007/s10495-010-0479-7
Yi W, Xu HT, Tian DF, Wu LQ, Zhang SQ, Wang L, Ji BW, Zhu XN, Okechi H, Liu G, Chen QX (2015) Photodynamic therapy mediated by 5-aminolevulinic acid suppresses gliomas growth by decreasing the microvessels. J Huazhong Univ Sci Technol Med Sci 35:259–264. https://doi.org/10.1007/s11596-015-1421-6
Anzengruber F, Avci P, de Freitas LF, Hamblin MR (2015) T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it? Photochem Photobiol Sci 14: 1492–1509 https://doi.org/10.1039/c4pp00455h
Hirschberg H, Berg K, Peng Q (2018) Photodynamic therapy mediated immune therapy of brain tumors. Neuroimmunol Neuroinflammation 5:27. https://doi.org/10.20517/2347-8659.2018.31
Etminan N, Peters C, Lakbir D, Bunemann E, Borger V, Sabel MC, Hanggi D, Steiger HJ, Stummer W, Sorg RV (2011) Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. Br J Cancer 105:961–969. https://doi.org/10.1038/bjc.2011.327
Li F, Cheng Y, Lu J, Hu R, Wan Q, Feng H (2011) Photodynamic therapy boosts anti-glioma immunity in mice: a dependence on the activities of T cells and complement C3. J Cell Biochem 112:3035–3043. https://doi.org/10.1002/jcb.23228
Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T (2009) Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 24:259–268. https://doi.org/10.1007/s10103-008-0539-1
Stables GI, Ash DV (1995) Photodynamic therapy. Cancer Treat Rev 21:311–323
Wang HW, Zhu TC, Putt ME, Solonenko M, Metz J, Dimofte A, Miles J, Fraker DL, Glatstein E, Hahn SM, Yodh AG (2005) Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt 10:14004. https://doi.org/10.1117/1.1854679
Quirk BJ, Brandal G, Donlon S, Vera JC, Mang TS, Foy AB, Lew SM, Girotti AW, Jogal S, LaViolette PS, Connelly JM, Whelan HT (2015) Photodynamic therapy (PDT) for malignant brain tumors – Where do we stand? Photodiagn Photodyn Ther 12: 530–544 https://doi.org/10.1016/j.pdpdt.2015.04.009
Mallidi S, Anbil S, Bulin AL, Obaid G, Ichikawa M, Hasan T (2016) Beyond the barriers of light penetration: strategies, perspectives and possibilities for photodynamic therapy. Theranostics 6:2458–2487. https://doi.org/10.7150/thno.16183
Quon H, Grossman CE, Finlay JC, Zhu TC, Clemmens CS, Malloy KM, Busch TM (2011) Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma. Photodiagn Photodyn Ther 8:75–85. https://doi.org/10.1016/j.pdpdt.2011.01.001
Leroy HA, Vermandel M, Vignion-Dewalle AS, Leroux B, Maurage CA, Duhamel A, Mordon S, Reyns N (2017) Interstitial photodynamic therapy and glioblastoma: light fractionation in a preclinical model. Lasers Surg Med 49:506–515. https://doi.org/10.1002/lsm.22620
Hirschberg H, Spetalen S, Carper S, Hole P, Tillung T, Madsen S (2006) Minimally invasive photodynamic therapy (PDT) for ablation of experimental rat glioma. Minim Invasive Neurosurg 49:135–142. https://doi.org/10.1055/s-2006-932216
Dupont C, Mordon S, Deleporte P, Reyns N, Vermandel M (2017) A novel device for intraoperative photodynamic therapy dedicated to glioblastoma treatment. Future Oncol 13:2441–2454. https://doi.org/10.2217/fon-2017-0261
Reyns N (2017) INtraoperative photoDYnamic Therapy of GliOblastoma (INDYGO). https://clinicaltrials.gov/ct2/show/record/NCT03048240?view=record
Bechet D, Mordon SR, Guillemin F, Barberi-Heyob MA (2014) Photodynamic therapy of malignant brain tumours: a complementary approach to conventional therapies. Cancer Treat Rev 40:229–241. https://doi.org/10.1016/j.ctrv.2012.07.004
Davies N, Wilson BC (2007) Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring. Photodiagn Photodyn Ther 4:202–212. https://doi.org/10.1016/j.pdpdt.2007.06.002
Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H, Stummer W, Baumgartner R (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39:386–393. https://doi.org/10.1002/lsm.20507
Yassine A-A, Kingsford W, Xu Y, Cassidy J, Lilge L, Betz V (2018) Automatic interstitial photodynamic therapy planning via convex optimization. Biomed Opt Express 9:898–920. https://doi.org/10.1364/BOE.9.000898
Shafirstein G, Bellnier D, Oakley E, Hamilton S, Potasek M, Beeson K, Parilov E (2017) Interstitial Photodynamic Therapy-A Focused Review. Cancers (Basel) 9 https://doi.org/10.3390/cancers9020012
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9
Lee I, Kalkanis S, Hadjipanayis CG (2016) Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas. Neurosurgery 79(Suppl 1):S24–Ss34. https://doi.org/10.1227/neu.0000000000001443
Senders JT, Muskens IS, Schnoor R, Karhade AV, Cote DJ, Smith TR, Broekman ML (2017) Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results. Acta Neurochir 159:151–167. https://doi.org/10.1007/s00701-016-3028-5
Lakomkin N, Hadjipanayis CG (2018) Fluorescence-guided surgery for high-grade gliomas. J Surg Oncol 118:356–361 https://doi.org/10.1002/jso.25154
He J, Yang L, Yi W, Fan W, Wen Y, Miao X, Xiong L (2017) Combination of fluorescence-guided surgery with photodynamic therapy for the treatment of cancer. Mol Imaging 16:1536012117722911. https://doi.org/10.1177/1536012117722911
Kou J, Dou D, Yang L (2017) Porphyrin photosensitizers in photodynamic therapy and its applications. Oncotarget 8:81591–81603. https://doi.org/10.18632/oncotarget.20189
Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Dougherty TJ (2006) Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX. Lasers Surg Med 38:439–444. https://doi.org/10.1002/lsm.20340
Ormond AB, Freeman HS (2013) Dye sensitizers for photodynamic therapy. Materials (Basel) 6:817–840. https://doi.org/10.3390/ma6030817
Zhang J, Jiang C, Figueiro Longo JP, Azevedo RB, Zhang H, Muehlmann LA (2018) An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharm Sin B 8:137–146. https://doi.org/10.1016/j.apsb.2017.09.003
Hiramatsu R, Kawabata S, Miyatake S, Kuroiwa T, Easson MW, Vicente MG (2011) Application of a novel boronated porphyrin (H(2)OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg Med 43:52–58. https://doi.org/10.1002/lsm.21026
Hill JS, Kahl SB, Stylli SS, Nakamura Y, Koo MS, Kaye AH (1995) Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc Natl Acad Sci USA 92:12126–12130
Hill JS, Kahl SB, Kaye AH, Stylli SS, Koo MS, Gonzales MF, Vardaxis NJ, Johnson CI (1992) Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc Natl Acad Sci USA 89:1785–1789
Josefsen LB, Boyle RW (2008) Photodynamic therapy: novel third-generation photosensitizers one step closer? Br J Pharmacol 154:1–3. https://doi.org/10.1038/bjp.2008.98
Zhang J, Jiang C, Figueiró Longo JP, Azevedo RB, Zhang H, Muehlmann LA (2018) An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharm Sin B 8:137–146. https://doi.org/10.1016/j.apsb.2017.09.003
Bechet D, Auger F, Couleaud P, Marty E, Ravasi L, Durieux N, Bonnet C, Plenat F, Frochot C, Mordon S, Tillement O, Vanderesse R, Lux F, Perriat P, Guillemin F, Barberi-Heyob M (2015) Multifunctional ultrasmall nanoplatforms for vascular-targeted interstitial photodynamic therapy of brain tumors guided by real-time MRI. Nanomedicine 11: 657–670 https://doi.org/10.1016/j.nano.2014.12.007
Thomas E, Colombeau L, Gries M, Peterlini T, Mathieu C, Thomas N, Boura C, Frochot C, Vanderesse R, Lux F, Barberi-Heyob M, Tillement O (2017) Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma. Int J Nanomed 12:7075–7088. https://doi.org/10.2147/ijn.s141559
Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo YE, Woolliscroft MJ, Sugai JV, Johnson TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD (2006) Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 12:6677–6686. https://doi.org/10.1158/1078-0432.Ccr-06-0946
Meyers JD, Cheng Y, Broome AM, Agnes RS, Schluchter MD, Margevicius S, Wang X, Kenney ME, Burda C, Basilion JP (2015) Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer. Part Part Syst Charact 32: 448–457 https://doi.org/10.1002/ppsc.201400119
Rajora MA, Ding L, Valic M, Jiang W, Overchuk M, Chen J, Zheng G (2017) Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00732a Click here for additional data file. Chem Sci 8:5371–5384. https://doi.org/10.1039/c7sc00732a
Tang XL, Wu J, Lin BL, Cui S, Liu HM, Yu RT, Shen XD, Wang TW, Xia W (2018) Near-infrared light-activated red-emitting upconverting nanoplatform for T1-weighted magnetic resonance imaging and photodynamic therapy. Acta Biomater 74:360–373. https://doi.org/10.1016/j.actbio.2018.05.017
Tsai YC, Vijayaraghavan P, Chiang WH, Chen HH, Liu TI, Shen MY, Omoto A, Kamimura M, Soga K, Chiu HC (2018) Targeted delivery of functionalized upconversion nanoparticles for externally triggered photothermal/photodynamic therapies of brain glioblastoma. Theranostics 8:1435–1448. https://doi.org/10.7150/thno.22482
Hadjipanayis CG, Widhalm G, Stummer W (2015) What is the surgical benefit of utilizing 5-ALA for fluorescence-guided surgery of malignant gliomas? Neurosurgery 77:663–673. https://doi.org/10.1227/NEU.0000000000000929
Valdes PA, Bekelis K, Harris BT, Wilson BC, Leblond F, Kim A, Simmons NE, Erkmen K, Paulsen KD, Roberts DW (2014) 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo. Neurosurgery 10:74–83. https://doi.org/10.1227/NEU.0000000000000117
Stummer W, Reulen HJ, Novotny A, Stepp H, Tonn JC (2003) Fluorescence-guided resections of malignant gliomas–an overview. Acta neurochirurgica Supplement 88:9–12
Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, Nambu E, Pyko IV, Hayashi Y, Hamada JI (2011) Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 104:798–807. https://doi.org/10.1038/bjc.2011.12
Yang X, Li W, Palasuberniam P, Myers KA, Wang C, Chen B (2015) Effects of silencing heme biosynthesis enzymes on 5-Aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy. Photochem Photobiol 91:923–930. https://doi.org/10.1111/php.12454
Kaneko S, Kaneko S (2016) Fluorescence-guided resection of malignant glioma with 5-ALA. Int J Biomed Imaging 2016: 11 https://doi.org/10.1155/2016/6135293
Johansson A, Faber F, Kniebuhler G, Stepp H, Sroka R, Egensperger R, Beyer W, Kreth FW (2013) Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis. Lasers Surg Med 45:225–234. https://doi.org/10.1002/lsm.22126
Ahn PH, Finlay JC, Gallagher-Colombo SM, Quon H, O’Malley BW Jr, Weinstein GS, Chalian A, Malloy K, Sollecito T, Greenberg M, Simone CB 2nd, McNulty S, Lin A, Zhu TC, Livolsi V, Feldman M, Mick R, Cengel KA, Busch TM (2018) Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy. Photodiagn Photodyn Ther 21:28–35. https://doi.org/10.1016/j.pdpdt.2017.10.015
Tetard M-C, Vermandel M, Mordon S, Lejeune J-P, Reyns N (2014) Experimental use of photodynamic therapy in high grade gliomas: a review focused on 5-aminolevulinic acid. Photodiagn Photodyn Ther 11:319–330. https://doi.org/10.1016/j.pdpdt.2014.04.004
Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempski O, Plesnila N, Wietzorrek J, Reulen HJ (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45:160–169
Tsai JC, Hsiao YY, Teng LJ, Chen CT, Kao MC (1999) Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Lasers Surg Med 24:296–305
Madsen Steen J, Sun C-H, Tromberg Bruce J, Hirschberg H (2001) Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy. Lasers Surg Med 29:406–412. https://doi.org/10.1002/lsm.10005
Busch TM, Xing X, Yu G, Yodh A, Wileyto EP, Wang HW, Durduran T, Zhu TC, Wang KK (2009) Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. Photochem Photobiol Sci 8:1683–1693. https://doi.org/10.1039/b9pp00004f
Hirschberg H, Sun C-H, Tromberg BJ, Madsen SJ (2002) ALA- and ALA-ester-mediated photodynamic therapy of human glioma spheroids. J Neuro-Oncol 57:1–7. https://doi.org/10.1023/A:1015784926550
Olzowy B, Hundt CS, Stocker S, Bise K, Reulen HJ, Stummer W (2002) Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J Neurosurg 97:970–976. https://doi.org/10.3171/jns.2002.97.4.0970
Hirschberg H, Sorensen DR, Angell-Petersen E, Peng Q, Tromberg B, Sun CH, Spetalen S, Madsen S (2006) Repetitive photodynamic therapy of malignant brain tumors. J Environ Pathol Toxicol Oncol 25:261–279
Tetard M-C, Vermandel M, Leroy H-A, Leroux B, Maurage C-A, Lejeune J-P, Mordon S, Reyns N (2016) Interstitial 5-ALA photodynamic therapy and glioblastoma: Preclinical model development and preliminary results. Photodiagn Photodyn Ther 13:218–224. https://doi.org/10.1016/j.pdpdt.2015.07.169
Hefti M, Albert I, Luginbuehl V (2012) Phenytoin reduces 5-aminolevulinic acid-induced protoporphyrin IX accumulation in malignant glioma cells. J Neuro-Oncol 108:443–450. https://doi.org/10.1007/s11060-012-0857-9
Lawrence JE, Steele CJ, Rovin RA, Belton RJ, Winn RJ (2016) Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells. J Neuro-Oncol 127:15–21. https://doi.org/10.1007/s11060-015-2012-x
Grabb PA, Gilbert MR (1995) Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg 82:1053–1058. https://doi.org/10.3171/jns.1995.82.6.1053
Wang W, Tabu K, Hagiya Y, Sugiyama Y, Kokubu Y, Murota Y, Ogura S-i, Taga T (2017) Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. Sci Rep 7: 42070 https://doi.org/10.1038/srep42070.https://www.nature.com/articles/srep42070#supplementary-information
Blake E, Curnow A (2010) The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol 86:1154–1160. https://doi.org/10.1111/j.1751-1097.2010.00770.x
Chen X, Wang C, Teng L, Liu Y, Chen X, Yang G, Wang L, Liu H, Liu Z, Zhang D, Zhang Y, Guan H, Li X, Fu C, Zhao B, Yin F, Zhao S (2014) Calcitriol enhances 5-aminolevulinic acid-induced fluorescence and the effect of photodynamic therapy in human glioma. Acta Oncol 53:405–413. https://doi.org/10.3109/0284186x.2013.819993
Ishikawa T, Kajimoto Y, Inoue Y, Ikegami Y, Kuroiwa T (2015) Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor. Adv Cancer Res 125:197–216. https://doi.org/10.1016/bs.acr.2014.11.008
Fisher CJ, Niu C, Foltz W, Chen Y, Sidorova-Darmos E, Eubanks JH, Lilge L (2017) ALA-PpIX mediated photodynamic therapy of malignant gliomas augmented by hypothermia. PLoS ONE 12:e0181654. https://doi.org/10.1371/journal.pone.0181654
Semyachkina-Glushkovskaya O, Kurths J, Borisova E, Sokolovski S, Mantareva V, Angelov I, Shirokov A, Navolokin N, Shushunova N, Khorovodov A, Ulanova M, Sagatova M, Agranivich I, Sindeeva O, Gekalyuk A, Bodrova A, Rafailov E (2017) Photodynamic opening of blood-brain barrier. Biomed Opt Express 8:5040–5048. https://doi.org/10.1364/BOE.8.005040
Kostron H, Fritsch E, Grunert V (1988) Photodynamic therapy of malignant brain tumours: a phase I/II trial. Br J Neurosurg 2:241–248
Rosenthal MA, Kavar B, Hill JS, Morgan DJ, Nation RL, Stylli SS, Basser RL, Uren S, Geldard H, Green MD, Kahl SB, Kaye AH (2001) Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J Clin Oncol 19:519–524. https://doi.org/10.1200/jco.2001.19.2.519
Schmidt MH, Meyer GA, Reichert KW, Cheng J, Krouwer HG, Ozker K, Whelan HT (2004) Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 67:201–207
Lyons M, Phang I, Eljamel S (2012) The effects of PDT in primary malignant brain tumours could be improved by intraoperative radiotherapy. Photodiagn Photodyn Ther 9:40–45. https://doi.org/10.1016/j.pdpdt.2011.12.001
Eljamel MS, Goodman C, Moseley H (2008) ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 23:361–367. https://doi.org/10.1007/s10103-007-0494-2
Schwartz C, Rühm A, Tonn J-C, Kreth S, Kreth F-W (2015) Surg-25interstitial photodynamic therapy of de-novo glioblastoma multiforme who IV. Neuro-Oncology 17:v219–v220. https://doi.org/10.1093/neuonc/nov235.25
Dupont C, Vermandel M, Leroy HA, Quidet M, Lecomte F, Delhem N, Mordon S, Reyns N (2018) INtraoperative photoDYnamic therapy for glioblastomas: study protocol for a phase I clinical trial. Neurosurgery https://doi.org/10.1093/neuros/nyy324
Vermandel M, Dupont C, Quidet M, Lecomte F, Lerhun E, Mordon S, Betrouni N, Reyns N (2017) Set-up of the first pilot study on intraopertive 5-ALA PDT: INDYGO trial. Photodiagn Photodyn Ther 17:A21. https://doi.org/10.1016/j.pdpdt.2017.01.048
Krishnamurthy S, Powers SK, Witmer P, Brown T (2000) Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med 27:224–234
Anderson I, Naylor T, McKinlay J, Sivakumar G (2015) Intra-operative acidosis during 5-aminolevulinic acid assisted glioma resection. BMJ Case Reports 2015: bcr2014207904 https://doi.org/10.1136/bcr-2014-207904
Chung IW, Eljamel S (2013) Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection. Photodiagn Photodyn Ther 10:362–367. https://doi.org/10.1016/j.pdpdt.2013.03.007
Quon H, Grossman CE, King RL, Putt M, Donaldson K, Kricka L, Finlay J, Zhu T, Dimofte A, Malloy K, Cengel KA, Busch TM (2010) Interference with the Jaffe method for creatinine following 5-aminolevulinic acid administration. Photodiagn Photodyn Ther 7:268–274. https://doi.org/10.1016/j.pdpdt.2010.07.008
Webber J, Kessel D, Fromm D (1997) Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 68:31–37. https://doi.org/10.1006/jsre.1997.5004
Acknowledgements
Authors TMB and GMC acknowledge NIH/NCI grants P01-CA087971 and R01-CA85831 for support during the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Mahmoudi, K., Garvey, K.L., Bouras, A. et al. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol 141, 595–607 (2019). https://doi.org/10.1007/s11060-019-03103-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03103-4